A bioequivalence study of proposed bevacizumab biosimilar, MYL-14020 (A) vs EU-Avastin (B) and US-Avastin (C).-MedSci.cn

A bioequivalence study of proposed bevacizumab biosimilar, MYL-14020 (A) vs EU-Avastin (B) and US-Avastin (C).

Socinski, MA; Hummel, M; Bosje, T; Shaw, A; Liu, MS; Baczkowski, M; Barve, A; Kothekar, M; Pennella, EJ

JOURNAL OF CLINICAL ONCOLOGY, 2017; 35 ( ):

科室
- - 订阅+
  - 更多科室
工具
服务